Immune Therapeutics, Inc. License Agreements
8 Contracts & Agreements
- Amendment No. 3 to License Agreement between the Company and Statera Biopharma, Inc. dated April 15, 2023 (Filed With SEC on April 20, 2023)
- Intellectual Property License Agreement, dated September 30, 2022, between Immune Therapeutics, Inc. and TaiwainJ Pharmaceuticals Co. Ltd (Filed With SEC on October 12, 2022)
- Agreement dated August 12, 2020 between Immune Therapeutics, Inc. and Cytocom, Inc. assigning all of .Immune Therapeutics right, title and interest in LDN and MENK in Developing... (Filed With SEC on November 16, 2020)
- PRC Amendment to The Second Amendment to the License Agreement effective December 31, 2018 with Cytocom, Inc. and signed May 12, 2020 (Filed With SEC on May 14, 2020)
- License Agreement dated January 15, 2020 with Forte Biotechnology Intl. Corp (Filed With SEC on May 14, 2020)
- Second Amendment to License Agreement with Cytocom Inc., effective December 31, 2018 and signed April 8, 2019 (Filed With SEC on May 14, 2020)
- Second Amendment to License Agreement by and between: Cytocom Inc. and Immune Therapeutics Inc., signed April 8, 2019 (Filed With SEC on May 20, 2019)
- Patent License Agreement dated September 24, 2014 between Dr. Jill P. Smith, LDN Research Group LLC and Cytocom, Inc. and related agreements (Filed With SEC on April 2, 2018)
